作者
Daniel YC Heng, Wanling Xie, Meredith M Regan, Mark A Warren, Ali Reza Golshayan, Chakshu Sahi, Bernhard J Eigl, J Dean Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J Knox, Kim N Chi, Christian Kollmannsberger, David F McDermott, William K Oh, Michael B Atkins, Ronald M Bukowski, Brian I Rini, Toni K Choueiri
发表日期
2009/12/1
期刊
Journal of clinical oncology
卷号
27
期号
34
页码范围
5794-5799
出版商
American Society of Clinical Oncology
简介
Purpose
There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF) –targeted therapy.
Methods
Baseline characteristics and outcomes on 645 patients with anti-VEGF therapy–naïve metastatic RCC were collected from three US and four Canadian cancer centers. Cox proportional hazards regression, followed by bootstrap validation, was used to identify independent prognostic factors for OS.
Results
The median OS for the whole cohort was 22 months (95% CI, 20.2 to 26.5 months), and the median follow-up was 24.5 months. Overall, 396, 200, and 49 patients were treated with sunitinib, sorafenib, and bevacizumab, respectively. Four of the five adverse prognostic factors according to the Memorial Sloan-Kettering Cancer Center (MSKCC) were independent predictors of short survival …
引用总数
学术搜索中的文章
DYC Heng, W Xie, MM Regan, MA Warren… - Journal of clinical oncology, 2009